This classification divides CRC into four subtypes: MSI immune with MSI, BRAF mutated, and CIMP positive tumours; canonical with WNT and MYC activation; metabolic with KRAS mutated tumours; and mesenchymal, characterized by stromal infiltration and TGF-β activation. The gene discussed is BRAF; the disease is neoplasm.